SecBot SecBot
SECBOTREPLAY Home › Report › PRAX

PRAX · Praxis Precision Medicines announced FDA acceptance of its NDA for…

Praxis Precision Medicines, Inc. · PRESS-RELEASE filed Mar 30, 2026 at 16:01 ET

At the news

BULLISHIMPACT 8/10

PRESS-RELEASE filed Mar 30, 2026 at 16:01 ET

Praxis Precision Medicines announced FDA acceptance of its NDA for relutrigine, a first-in-class therapy for SCN2A and SCN8A developmental and epileptic encephalopathies, with a PDUFA target action date of September 27, 2026. The filing is supported by strong Phase 2 data showing robust seizure reduction, and the drug has multiple expedited designations including Breakthrough Therapy and Rare Pediatric Disease Designation.

  • FDA accepted NDA for relutrigine with priority review and PDUFA date of September 27, 2026
  • Relutrigine is first potential disease-modifying therapy for SCN2A/SCN8A DEEs, which currently have no approved targeted treatments
  • NDA supported by positive interim results from EMBOLD study, stopped early for efficacy
  • Relutrigine has Orphan Drug, Rare Pediatric Disease, and Breakthrough Therapy Designations

Replay the market's reaction

Step through every 5 minutes around the news, then see how it compares with similar events.

Subscribe for Full Access